Mate I know a lot of people are now singing Paul's praises, but...

Mate I know a lot of people are now singing Paul's praises, but he still has much to prove in my opinion. He's raised when he said he wouldn't, blew out timelines he said he'd deliver, and rarely if ever replies to shareholders questions. He also runs this company as if it's a private entity employing his partner and mates in the process. The BH deal reads well from what little we've seen thus far, but quite frankly he's failed to deliver any meaningful returns to investors since listing (not counting the odd fomo spike).

This BH deal will take a while to playout too. I dont believe we'll see any serious revenues for at least two quarters (possibly even more) until Striate+ penetrates the market.

OCC has the potential to easily hit a 500Mcap and go on with it, but until that day comes I will continue to hold his feet to the fire.

I will give credit where credit's due though, we still have a very low SOI unlike some other biotech's which can be both a blessing and a curse. So credit for not diluting the shit out of us I suppose
Thanks, Paul.